title: The next generation of therapeutics for chronic kidney disease.
abstract: Chronic kidney disease (CKD) represents a leading cause of death in the United States. There is no cure for this disease, with current treatment strategies relying on blood pressure control through blockade of the renin-angiotensin system. Such approaches only delay the development of end-stage kidney disease and can be associated with serious side effects. Recent identification of several novel mechanisms contributing to CKD development - including vascular changes, loss of podocytes and renal epithelial cells, matrix deposition, inflammation and metabolic dysregulation - has revealed new potential therapeutic approaches for CKD. This Review assesses emerging strategies and agents for CKD treatment, highlighting the associated challenges in their clinical development.
authors.affiliation: Biotechnology Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Breyer
authors.affiliation: Renal Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
authors.forename: Katalin
authors.initials: K
authors.lastname: Susztak
mesh_terms: D000818:Animals; D005355:Fibrosis; D006801:Humans; D051379:Mice; D012076:Renal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D012076:Renal Agents